Welcome to our dedicated page for Vireo Growth news (Ticker: VREOF), a resource for investors and traders seeking the latest updates and insights on Vireo Growth stock.
Vireo Growth Inc. (VREOF) generates a steady flow of news driven by its activities in the cannabis industry, including medical and adult-use operations, multi-state expansion, and corporate transactions. As a company that describes itself as a pioneering medical cannabis operator founded in 2014, Vireo uses press releases to communicate developments in its retail footprint, cultivation and production capacity, and strategic initiatives.
Recent news items highlight several key themes. One is geographic expansion and market entry. Vireo announced an Agreement and Plan of Merger to acquire Eaze Inc., a vertically integrated cannabis retailer and delivery technology platform with operations in California, Florida, and Colorado. The company states that this transaction is intended to mark its entry into California and Florida and to strengthen its position in Colorado, with Eaze becoming a wholly owned subsidiary upon closing.
Another recurring theme is M&A and capital structure activity. Vireo has reported entering into agreements to acquire a majority of Schwazze’s senior secured convertible notes, participating in a restructuring support agreement that contemplates an asset sale to a new entity to be majority-owned by Vireo, and negotiating an Asset Purchase Agreement to acquire Colorado dispensary assets from PharmaCann Inc. These announcements detail transaction terms, consideration in subordinate voting shares, and conditions such as regulatory approvals.
Operational updates also feature prominently. Vireo issued a release announcing the launch of adult-use cannabis sales in Minnesota at its Green Goods dispensaries, noting that it dispenses both medical and adult-use products at eight locations in the state. Quarterly earnings releases provide summaries of financial performance, state-by-state revenue, and non-GAAP metrics, accompanied by management commentary on integration of acquisitions and portfolio development.
Investors and observers who follow VREOF news can use this stream of announcements to monitor transaction progress, regulatory milestones, market entries, adult-use launches, litigation resolutions, and financial reporting updates, all of which are documented through Globe Newswire releases and linked SEC filings.
Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF), a cannabis company, has announced the release of its second quarter 2024 financial results on August 6, 2024, after market close. The company will host a conference call with investors on the same day at 4:30 p.m. ET to discuss the results. Interested parties can join the call by dialing 1-800-715-9871 (US and Canada, Toll-Free) or 1-646-307-1963 (International, Toll) with conference ID 3718174. A live audio webcast will also be available on the company's Investor Relations website.
Vireo Growth, formerly Goodness Growth Holdings, has announced that its subordinate voting shares will start trading under new ticker symbols from today, July 8, 2024. The shares will be listed as 'VREO' on the Canadian Securities Exchange (CSE) and as 'VREOF' on the OTCQX Market in the United States. This change aligns with the company's rebranding efforts and commitment to providing safe access, quality products, and great value to its customers.
Vireo Health International, Inc. announced a corporate name change to Goodness Growth Holdings, effective June 9, 2021, along with its Horizon Strategy for fiscal year 2022. The company anticipates FY22 revenue of $140 million to $180 million and adjusted EBITDA of $35 million to $55 million. It plans to open 6-10 additional Green Goods™ dispensaries and begin adult-use sales in New Mexico and New York in 2022. Vireo had approximately $40 million in cash as of March 31, 2021, and projects positive cash flow from operations in the first half of 2022.
Vireo Health International, Inc. supports the recent expansion of Minnesota's medical cannabis program, allowing the use of smokable cannabis flower. This change aims to enhance accessibility and affordability for patients, potentially decreasing reliance on illicit markets for cannabis products. Vireo's CEO, Dr. Kyle Kingsley, emphasized the initiative's role in improving public health and safety, particularly in combating opioid use. The company's commitment to scientific innovation is reflected in its operations across eight markets with 16 dispensaries.
Vireo Health International has announced it will host a series of online virtual events on June 8-9, 2021, aimed at both institutional and retail investors. The events include a video webcast featuring the executive leadership team, focusing on the company's long-term vision and financial outlook, and a conference call to discuss business updates. Chairman Kyle Kingsley expressed enthusiasm for sharing insights into Vireo's cannabis assets and expansion projects. Interested parties can register for the events in advance.
Vireo Health International reported first-quarter 2021 revenue of $13.2 million, an 8.8% increase year-over-year, and a 29.8% increase excluding former Pennsylvania subsidiaries. Gross profit rose to $5.6 million, or 42.6% of revenue, reflecting improved operational efficiency. The company is expanding its footprint in key markets like New York and Maryland, anticipating better growth prospects due to recent legislative changes. Despite a $7.0 million net loss, which is an improvement from last year, Vireo's focus on expansion and operational efficiency positions it for future growth.
Vireo Health International, a science-focused cannabis company, will announce its financial results for Q1 2021 on May 14, 2021, before market opens. The conference call will occur at 8:30 a.m. ET on the same day, allowing stakeholders to gain insights into the company's performance. Interested participants can register for the call via a specific link. Vireo operates in eight markets and manages 16 dispensaries, aiming for efficiency and innovation in cannabis production. For more details, visit vireohealth.com.
Vireo Health International, Inc. (CSE: VREO; OTCQX: VREOF) announced the launch of its first line of ground medical cannabis flower in New York, with an initial offering of four strains. Available in 3.5-gram and 7-gram jars, the product aims to improve patient accessibility and affordability. By September, the company plans to expand its selection to over 20 strains. Vireo's dispensaries will carry products from three state-registered growers, marking the largest selection of ground flower in New York. The initiative aligns with efforts to reduce reliance on illicit cannabis markets.
Vireo Health International has completed the expansion of its cannabis cultivation and processing facility in New Mexico. This strategic move includes the opening of two new retail dispensaries in Albuquerque and Las Cruces, pending regulatory approval. The expansion will increase cultivation capacity by up to eight times and create over 30 new jobs. The additional facilities aim to meet rising demand following recent adult-use legislation in the state. Vireo now operates four dispensaries in New Mexico, reinforcing its position in this growing market.
Vireo Health International, Inc. (CSE: VREO; OTCQX: VREOF) announced the successful sale of its former subsidiary, Ohio Medical Solutions, LLC, to Ayr Wellness, Inc. for $1.15 million in cash and a relief of $3.6 million in lease liabilities. Following this transaction, Vireo aims to enhance growth across its key markets: Arizona, Maryland, Minnesota, New Mexico, and New York. Chairman & CEO Dr. Kyle Kingsley highlighted improved operational strength and confidence in future opportunities, signaling a halt on further asset divestitures.